Business
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed fo
About this update from Palisade Bio, Inc.
[{"type":"image","alt":"Palisade Bio, Inc.","displaySize":"","headline":null,"caption":"Palisade Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VBDa4YPveOaoDW8bYlQJUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747","width":300,"height":77},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/VBDa4YPveOaoDW8bYlQJUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747","width":300,"height":77}},"lazy":false},{"type":"text","content":"Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD","length":114,"tagName":"p"},{"type":"text","content":"Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026","length":66,"tagName":"p"},{"type":"text","content":" Strong balance sheet expected to support execution through key clinical readouts","length":80,"tagName":"p"},{"type":"text","content":"Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations.","length":519,"tagName":"p"},{"type":"text","content":"Building on positive Phase 1a and Phase 1b ulcerative colitis cohort data previously reported, the Company recently reported results from the Phase 1b fibrostenotic Crohn’s disease (“FSCD”) cohort, extending the clinical support for the continued development of PALI-2108 across multiple inflammatory bowel disease (“IBD”) indications. The data demonstrated sustained exposure of the active metabolite above IC90 thresholds, along with favorable distribution to colon tissue, supporting consistent target engagement at the site of disease. In addition, pharmacodynamic findings showed modulation of key inflamm...